SeaStar Medical Holding Corporation
NCM: ICULive Quote
About SeaStar Medical Holding Corporation
Healthcare
Biotechnology
SeaStar Medical Holding Corporation, a commercial-stage medical device company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.
📊 Fundamental Analysis
SeaStar Medical Holding Corporation demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported 526.9% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is -295.2%, which indicates that capital utilization is currently under pressure.
At a current price of $3.71, ICU currently trades near the bottom of its 52-week range (14%), indicating potential value or weakness (Range: $2.07 - $13.50).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$11.11M
Trailing P/E
--
Forward P/E
-1.44
Beta (5Y)
-1.19
52W High
$13.50
52W Low
$2.07
Avg Volume
149K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App